Polyglycerol Functionalized 10 B Enriched Boron Carbide Nanoparticle as an Effective Bimodal Anticancer Nanosensitizer for Boron Neutron Capture and Photothermal Therapies.
Polyglycerol Functionalized 10 B Enriched Boron Carbide Nanoparticle as an Effective Bimodal Anticancer Nanosensitizer for Boron Neutron Capture and Photothermal Therapies.
复制标题
DOI：
10.1002/smll.202204044
复制
发表时间：
2022-08
期刊：
影响因子：
13.3
通讯作者：
Yuquan Wang;G. Reina;H. Kang;Xiaoxiao Chen;Y. Zou;Y. Ishikawa;Minoru Suzuki;N. Komatsu
中科院分区：
文献类型：
--
作者：
Yuquan Wang;G. Reina;H. Kang;Xiaoxiao Chen;Y. Zou;Y. Ishikawa;Minoru Suzuki;N. Komatsu
硼中子捕获疗法（BNCT）是一种非侵入性癌症治疗方法，利用中子照射后 10 B 的核裂变，副作用很小。虽然中子源已从核反应堆发展到紧凑型加速器，但只有硼苯丙氨酸和硼Cap酸钠这两种药物尽管其肿瘤特异性和/或保留性较低，但已在临床上使用了数十年。为了克服这些挑战，人们基于胶束、（生物）聚合物和无机纳米颗粒设计了各种含硼纳米材料或“纳米敏化剂”。其中，碳化硼等无机纳米粒子可以包含更高的 10 B含量，但成功的体内应用非常有限。此外，最近关于碳化硼光热效应的报道促使人们添加另一种光热疗法。在这项研究中，10B富集碳化硼（10B4C）纳米颗粒被聚甘油（PG）功能化，使10B4C-PG在生理环境中具有足够的分散性。药代动力学实验表明，10 B4 C-PG满足BNCT的以下三个要求； 1) 低内在毒性，2) 肿瘤/肿瘤组织中 10 B 浓度 (wt/wt) ≥ 20 ppm，3) 肿瘤/血液中 10 B 浓度≥ 3。体内研究表明，静脉注射 10 B4 C-PG 后进行中子照射可显着抑制癌症生长，并借助近红外光照射根除癌症。
Boron neutron capture therapy (BNCT) is a non-invasive cancer treatment with little adverse effect utilizing nuclear fission of 10 B upon neutron irradiation. While neutron source has been developed from a nuclear reactor to a compact accelerator, only two kinds of drugs, boronophenylalanine and sodium borocaptate, have been clinically used for decades despite their low tumor specificity and/or retentivity. To overcome these challenges, various boron-containing nanomaterials, or "nanosensitizers", have been designed based on micelles, (bio)polymers and inorganic nanoparticles. Among them, inorganic nanoparticles such as boron carbide can include a much higher 10 B content, but successful in vivo applications are very limited. Additionally, recent reports on the photothermal effect of boron carbide are motivating for the addition of another modality of photothermal therapy. In this study, 10 B enriched boron carbide (10 B4 C) nanoparticle is functionalized with polyglycerol (PG), giving 10 B4 C-PG with enough dispersibility in a physiological environment. Pharmacokinetic experiments show that 10 B4 C-PG fulfills the following three requirements for BNCT; 1) low intrinsic toxicity, 2) 10 B in tumor/tumor tissue (wt/wt) ≥ 20 ppm, and 3) 10 B concentrations in tumor/blood ≥ 3. In vivo study reveals that neutron irradiation after intravenous administration of 10 B4 C-PG suppresses cancer growth significantly and eradicates cancer with the help of near-infrared light irradiation.